日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer.

Pyrotinib 靶向 EGFR/GRP78 介导的高 EGFR 基因拷贝数胃癌细胞凋亡

Bao Lingbo, Wang Xudong, Liao Xiuyong, Li Dong, Li ChunXue, Dai Nan, Dai Xiaoyan, Yang Jing, Hu Nana, Tong Xueling, He Zhenjie, Zhao Yuancheng, Liu Zheng, Hu Yue, Shan Jinlu, Wang Dong, Li Mengxia, Chen Qian

Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study

对多纳非尼常见治疗相关不良事件及其与疗效的相关性进行分析:ZGDH3 研究的探索性分析

Bi, Feng; Qin, Shukui; Gu, Shanzhi; Bai, Yuxian; Chen, Zhendong; Wang, Zishu; Ying, Jieer; Lu, Yinying; Meng, Zhiqiang; Pan, Hongming; Yang, Ping; Zhang, Helong; Chen, Xi; Xu, Aibing; Cui, Chengxu; Zhu, Bo; Wu, Jian; Xin, Xiaoli; Wang, Jufeng; Shan, Jinlu; Chen, Junhui; Zheng, Zhendong; Xu, Li; Wen, Xiaoyu; You, Zhenyu; Ren, Zhenggang; Xu, Jianming; Du, Chengyou; Fan, Qingxia; Zhang, Longzhen; Tao, Min; Jiang, Da; Wang, Senming; Chen, Yongping; Sheng, Jifang; Zhuang, Xuelong; Wu, Jun

Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

晚期非小细胞肺癌中免疫检查点抑制剂的再次应用

Lin, Gen; Wang, Zhijie; Chu, Qian; Hu, Yi; Huang, Dingzhi; Wang, Jun; Yang, Fan; Zhong, Wenzhao; Zhou, Chengzhi; Zhu, Bo; Ai, Xinghao; Cao, Baoshan; Cao, Yabing; Chen, Mingqiu; Chen, Xiaohui; Chu, Tianqing; Duan, Jianchun; Fan, Yun; Fang, Yong; Feng, Shuitu; Feng, Weineng; Guo, Hui; Han, Chengbo; He, Yong; Hong, Shaodong; Hu, Jie; Huang, Meijuan; Huang, Yan; Jiang, Da; Jiang, Kan; Jiang, Richeng; Jin, Bo; Jin, Shi; Li, Jisheng; Li, Min; Li, Ziming; Li, Chao; Lin, Jie; Liu, Anwen; Liu, Si-Yang Maggie; Yutao, Liu; Liu, Zhefeng; Liu, Zhe; Liu, Zhenhua; Liu, Zhentian; Liu, Zhigang; Lu, Yuping; Lv, Tangfeng; Ma, Zhiyong; Miao, Qian; Peng, Min; Pu, Xingxiang; Ren, Xiu Bao; Shan, Jianzhen; Shan, Jinlu; Shen, Peng; Shen, Bo; Shi, Meiqi; Song, Yong; Song, Zhengbo; Su, ChunXia; Sun, Jianguo; Tian, Panwen; Wang, Jinliang; Wang, Feng; Wang, Huijuan; Wang, Jialei; Wang, Qian; Wang, Wenxian; Wang, Yan; Wu, Lin; Wu, Fang; Xia, Yang; Xie, Congying; Xie, Conghua; Xin, Tao; Xiong, Jianping; Xu, Haipeng; Xu, Song; Xu, Yiquan; Xu, Bin; Xu, Chunwei; Yan, Xiaolong; Yang, Zhenzhou; Yao, Wenxiu; Yu, Yao; Feng, Ye; Yu, Zongyang; Yu, Yongfeng; Yue, Dongsheng; Zhang, Haibo; Zhang, HongMei; Zhang, Li; Zhang, Longfeng; Zhang, Qiuyu; Zhang, Tongmei; Zhang, Bicheng; Zhao, Jun; Zhao, Mingfang; Zheng, Xiaobin; Zhong, Qiaofeng; Zhou, Jin; Zhou, Penghui; Zhu, Zhengfei; Zou, Juntao; Zou, Zihua

Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

iruplinalkib (WX-0593) 治疗 ALK 阳性克唑替尼耐药的晚期非小细胞肺癌患者的疗效和安全性:一项单臂、多中心 II 期研究 (INTELLECT)

Shi, Yuankai; Chen, Jianhua; Zhang, Helong; Zhang, Zhihong; Zhang, Yiping; Wang, Zhehai; Zhang, Shucai; Zhao, Jian; Liu, Chunling; Wang, Xiuwen; Zhao, Yanqiu; Hu, Changlu; Yang, Lei; Hao, Xuezhi; Wang, Lin; Liu, Yunpeng; Yu, Yan; Zhao, Jun; Wang, Mengzhao; Zhang, Liangming; Sun, Sanyuan; Hu, Yanping; Gu, Kangsheng; Hang, Xiaosheng; Shan, Jinlu; Zhang, Yu; Tan, Bangxian; Yang, Weihua; Yang, Runxiang; Si, Meimei; Geng, Huaize; Li, Hui; Kang, Xiaoyan

Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer

非小细胞肺癌免疫治疗继发性耐药的临床定义

Huang, Dingzhi; Lin, Gen; Chu, Qian; Hu, Yi; Wang, Jun; Wang, Zhijie; Yang, Fan; Zhong, Wenzhao; Zhou, Chengzhi; Zhu, Bo; Ai, Xinghao; Cao, Baoshan; Cao, Yabing; Chen, Mingqiu; Chen, Xiaohui; Chu, Tianqing; Duan, Jianchun; Fan, Yun; Fang, Yong; Feng, Shuitu; Feng, Weineng; Guo, Hui; Han, Chengbo; He, Yong; Hong, Shaodong; Hu, Jie; Huang, Meijuan; Huang, Yan; Jiang, Da; Jiang, Kan; Jiang, Richeng; Jin, Bo; Jin, Shi; Li, Jisheng; Li, Min; Li, Ziming; Li, Chao; Lin, Jie; Liu, Anwen; Liu, Si-Yang Maggie; Liu, Yutao; Liu, Zhefeng; Liu, Zhe; Liu, Zhenhua; Liu, Zhentian; Liu, Zhigang; Lu, Yuping; Lv, Tangfeng; Ma, Zhiyong; Miao, Qian; Peng, Min; Pu, Xingxiang; Ren, Xiu Bao; Shan, Jianzhen; Shan, Jinlu; Shen, Peng; Shen, Bo; Shi, Meiqi; Song, Yong; Song, Zhengbo; Su, ChunXia; Sun, Jianguo; Tian, Panwen; Wang, Jinliang; Wang, Feng; Wang, Huijuan; Wang, Jialei; Wang, Qian; Wang, Wenxian; Wang, Yan; Wu, Lin; Wu, Fang; Xia, Yang; Xie, Congying; Xie, Conghua; Xin, Tao; Xiong, Jianping; Xu, Haipeng; Xu, Song; Xu, Yiquan; Xu, Bin; Xu, Chunwei; Yan, Xiaolong; Yang, Zhenzhou; Yao, Wenxiu; Yu, Yao; Feng, Ye; Yu, Zongyang; Yu, Yongfeng; Yue, Dongsheng; Zhang, Haibo; Zhang, HongMei; Zhang, Li; Zhang, Longfeng; Zhang, Qiuyu; Zhang, Tongmei; Zhang, Bicheng; Zhao, Jun; Zhao, Mingfang; Zheng, Xiaobin; Zhong, Fengqiao; Zhou, Jin; Zhou, Penghui; Zhu, Zhengfei; Zou, Juntao; Zou, Zihua

Analysis of risk factors and gene mutation characteristics of different metastatic sites of lung cancer

肺癌不同转移部位的风险因素和基因突变特征分析

Wang, Bin; Chen, Shu; Xiao, He; Zhang, Jiao; Liang, Dandan; Shan, Jinlu; Zou, Hua

The Predictive Value of Three Variables in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Based Combination Therapies in Randomized Clinical Trials: A Systematic Review and Meta-Analysis

随机临床试验中,三个变量对接受免疫联合疗法治疗的转移性肾细胞癌患者的预测价值:系统评价和荟萃分析

Hou, Min; Xing, Haiyan; He, Shuangshuang; Yang, Xue; Peng, Dan; Li, Yang; Zhang, Qing; Zhang, Pan; Ma, Yunqi; Li, Juan; Shan, Jinlu; Liu, Yao

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

多那非尼与索拉非尼一线治疗不可切除或转移性肝细胞癌:一项随机、开放标签、平行对照的II/III期试验

Qin, Shukui; Bi, Feng; Gu, Shanzhi; Bai, Yuxian; Chen, Zhendong; Wang, Zishu; Ying, Jieer; Lu, Yinying; Meng, Zhiqiang; Pan, Hongming; Yang, Ping; Zhang, Helong; Chen, Xi; Xu, Aibing; Cui, Chengxu; Zhu, Bo; Wu, Jian; Xin, Xiaoli; Wang, Jufeng; Shan, Jinlu; Chen, Junhui; Zheng, Zhendong; Xu, Li; Wen, Xiaoyu; You, Zhenyu; Ren, Zhenggang; Liu, Xiufeng; Qiu, Meng; Wu, Liqing; Chen, Feng

A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1

一项随机、双盲、安慰剂对照研究,评估B细胞淋巴瘤2同源性3模拟物棉酚联合多西他赛和顺铂治疗高表达脱嘌呤/脱嘧啶核酸内切酶1的晚期非小细胞肺癌的疗效。

Wang, Yuxiao; Li, Xuemei; Zhang, Liang; Li, Mengxia; Dai, Nan; Luo, Hao; Shan, Jinlu; Yang, Xueqin; Xu, Mingfang; Feng, Yan; Xu, Chengxiong; Qian, Chengyuan; Wang, Dong

HLA-DQB1 expression on tumor cells is a novel favorable prognostic factor for relapse in early-stage lung adenocarcinoma

肿瘤细胞上HLA-DQB1的表达是早期肺腺癌复发的一个新型有利预后因素

Zhang, Liang; Li, Mengxia; Deng, Bo; Dai, Nan; Feng, Yan; Shan, Jinlu; Yang, Yuxin; Mao, Chengyi; Huang, Ping; Xu, Chengxiong; Wang, Dong